• Je něco špatně v tomto záznamu ?

Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma

S. Katayama, B. Pradere, NC. Grossman, AM. Potretzke, SA. Boorjian, A. Ghoreifi, S. Daneshmand, H. Djaladat, JP. Sfakianos, A. Mari, ZE. Khene, D. D'andrea, N. Hayakawa, K. Fujita, A. Heindenreich, JD. Raman, M. Roumiguié, F. Abdollah, A. Breda,...

. 2024 ; 38 (11) : 1156-1163. [pub] 20240925

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003656

Background: Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy (RNU) pathology. Methods: In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Results: Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p = 0.007). Downgrading was comparable across all tumor locations. On multivariate analyses, middle ureteral location was significantly associated with a low probability of grade concordance (odds ratio [OR] 0.59; 95% confidence interval [CI], 0.35-1.00; p = 0.049) and an increased risk of upgrading (OR 2.80; 95% CI, 1.20-6.52; p = 0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Conclusions: Middle ureteral tumors diagnosed to be low grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counseling and shared decision making regarding the choice of kidney sparing vs RNU.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Cantonal Hospital of Lucerne Lucerne Switzerland

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Faculty of Medicine Kindai University Osakasayama Japan

Department of Urology Fundació Puigvert Autonoma University of Barcelona Barcelona Spain

Department of Urology Hospital Pontchaillou CHU Rennes Rennes France

Department of Urology Icahn School of Medicine at Mount Sinai Hospital New York New York USA

Department of Urology Institut Universitaire du Cancer Toulouse France

Department of Urology Mayo Clinic Rochester Minnesota USA

Department of Urology Norris Comprehensive Cancer Center University of Southern California Los Angeles California USA

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology St Marianna University School of Medicine Kanagawa Japan

Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA

Department of Urology Uro Oncology Robot Assisted and Reconstructive Surgery University of Cologne Cologne Germany

Department of Urology Weill Cornell Medical College New York New York USA

Division of Urology Penn State Health Milton S Hershey Medical Center Hershey Pennsylvania USA

GRC 5 Predictive Onco Uro AP HP Urology Pitie Salpetriere Hospital Sorbonne University Paris France

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Unit of Oncologic Minimally Invasive Urology and Andrology Careggi Hospital Department of Clinical and Experimental Medicine University of Florence Firenze Italy

Vattikuti Urology Institute Center for Outcomes Research Analytics and Evaluation Henry Ford Health System Vattikuti Urology Institute Detroit Michigan USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003656
003      
CZ-PrNML
005      
20250206104604.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/end.2024.0335 $2 doi
035    __
$a (PubMed)39264866
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283772457)
245    10
$a Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma / $c S. Katayama, B. Pradere, NC. Grossman, AM. Potretzke, SA. Boorjian, A. Ghoreifi, S. Daneshmand, H. Djaladat, JP. Sfakianos, A. Mari, ZE. Khene, D. D'andrea, N. Hayakawa, K. Fujita, A. Heindenreich, JD. Raman, M. Roumiguié, F. Abdollah, A. Breda, M. Fontana, M. Rouprêt, V. Margulis, PI. Karakiewicz, M. Araki, Y. Nasu, SF. Shariat
520    9_
$a Background: Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy (RNU) pathology. Methods: In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Results: Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p = 0.007). Downgrading was comparable across all tumor locations. On multivariate analyses, middle ureteral location was significantly associated with a low probability of grade concordance (odds ratio [OR] 0.59; 95% confidence interval [CI], 0.35-1.00; p = 0.049) and an increased risk of upgrading (OR 2.80; 95% CI, 1.20-6.52; p = 0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Conclusions: Middle ureteral tumors diagnosed to be low grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counseling and shared decision making regarding the choice of kidney sparing vs RNU.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a ureteroskopie $x metody $7 D018666
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lidé středního věku $7 D008875
650    12
$a stupeň nádoru $7 D060787
650    12
$a nádory močovodu $x patologie $x chirurgie $7 D014516
650    _2
$a nefroureterektomie $x metody $7 D000074682
650    _2
$a ureter $x patologie $x chirurgie $x diagnostické zobrazování $7 D014513
650    _2
$a karcinom z přechodných buněk $x chirurgie $x patologie $7 D002295
650    _2
$a nádory ledvin $x patologie $x chirurgie $7 D007680
650    _2
$a biopsie $7 D001706
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a klinická relevance $7 D000092522
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000277688558
700    1_
$a Grossman, Nico C $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Cantonal Hospital of Lucerne, Lucerne, Switzerland $1 https://orcid.org/0000000186986461
700    1_
$a Potretzke, Aaron M $u Department of Urology, Mayo Clinic, Rochester, Minnesota, USA $1 https://orcid.org/0000000346191773
700    1_
$a Boorjian, Stephen A $u Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Ghoreifi, Alireza $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
700    1_
$a Daneshmand, Siamak $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA $1 https://orcid.org/0000000162249598 $7 ntk20221160751
700    1_
$a Djaladat, Hooman $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
700    1_
$a Sfakianos, John P $u Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA
700    1_
$a Mari, Andrea $u Unit of Oncologic Minimally-Invasive Urology and Andrology - Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy
700    1_
$a Khene, Zine-Eddine $u Department of Urology, Hospital Pontchaillou, CHU Rennes, Rennes, France
700    1_
$a D'andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Hayakawa, Nozomi $u Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan
700    1_
$a Fujita, Kazutoshi $u Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan
700    1_
$a Heindenreich, Axel $u Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Surgery, University of Cologne, Cologne, Germany
700    1_
$a Raman, Jay D $u Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
700    1_
$a Roumiguié, Mathieu $u Department of Urology, Institut Universitaire du Cancer, Toulouse, France
700    1_
$a Abdollah, Firas $u Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Health System, Vattikuti Urology Institute, Detroit, Michigan, USA
700    1_
$a Breda, Alberto $u Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain
700    1_
$a Fontana, Matteo $u Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain
700    1_
$a Rouprêt, Morgan $u GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France
700    1_
$a Margulis, Vitaly $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Araki, Motoo $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Nasu, Yasutomo $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
773    0_
$w MED00002655 $t Journal of endourology $x 1557-900X $g Roč. 38, č. 11 (2024), s. 1156-1163
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39264866 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104559 $b ABA008
999    __
$a ok $b bmc $g 2263421 $s 1239663
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 11 $d 1156-1163 $e 20240925 $i 1557-900X $m Journal of endourology $n J Endourol $x MED00002655
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace